Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting
Prospective single-arm study of 1,083 patients receiving favipiravir in India, showing one death and no new safety issues.
Reddy et al., 3 May 2022, prospective, India, peer-reviewed, 19 authors, study period December 2020 - June 2021, trial
CTRI/2020/11/029263.
Contact:
sagar.bhagat@glenmarkpharma.com.
Abstract: International Journal of General Medicine
Dovepress
open access to scientific and medical research
International Journal of General Medicine
For personal use only.
Open Access Full Text Article
C L I N I C A L T R I A L R E P O RT
Evaluation of the Safety and Efficacy of Favipiravir
in Adult Indian Patients with Mild-to-Moderate
COVID-19 in a Real-World Setting
Pavan Kumar Reddy 1 , Saiprasad Patil 2 , Akash Khobragade 3 , Akash Balki 4 , Aneesh Raj 5 ,
Mrunalini Kalikar 6 , Raghavendra Reddy 7 , Ravindra Shinde 8 , Jayanthi CR 9 , Abhinandan Mutha 10 ,
Nagaraju Boyilla 11 , Girish C Rajadhyaksha 12 , Niteen Karnik 13 , Sagar Bhagat 2 , Amol Pendse 14 ,
Priyanka Dhage 15 , Wen Wu 16 , Shabbir Rangwala 14 , Hanmant Barkate 2
1
Critical Care Medicine, Care Hospital, Hyderabad, Telangana, India; 2Global Medical Affairs, Glenmark Pharmaceuticals Ltd., Mumbai, Maharashtra,
India; 3St. George’s Hospital, Mumbai, Maharashtra, India; 4Shree Hospital & Critical Care Center, Nagpur, Maharashtra, India; 5NIMS Medicity,
Trivandrum, Kerala, India; 6Department of Pharmacology, Government Medical College, Nagpur, Maharashtra, India; 7Renova Neelima Hospitals,
Hyderabad, Telangana, India; 8Respiratory Medicine, Dr Vasantrao Pawar Medical College, Nashik, Maharashtra, India; 9Bangalore Medical College,
Bengaluru, Karnataka, India; 10Siddhi Hospital, Nasik, Maharashtra, India; 11Aster Prime Hospital, Hyderabad, Telangana, India; 12Department of
Medicine, BYL Medical college & Nair Hospital, Mumbai, Maharashtra, India; 13Department of Medicine, LT Medical College & Sion Hospital, Mumbai,
Maharashtra, India; 14Clinical Research Operations, Glenmark Pharmaceuticals Ltd., Mumbai, Maharashtra, India; 15Glenmark Pharmaceuticals Ltd.,
Mumbai, Maharashtra, India; 16Glenmark Pharmaceuticals Ltd., Waterford, UK
Correspondence: Sagar Bhagat, Tel +919930553638, Email Sagar.Bhagat@glenmarkpharma.com
Purpose: To evaluate the safety and efficacy of favipiravir, which is prescribed for the treatment of patients with mild-to-moderate
coronavirus disease 2019 (COVID-19) in India.
Patients and Methods: This was a prospective, open-label, multicenter, single-arm postmarketing study conducted in India. Patients
with mild-to-moderate COVID-19 received favipiravir (3600 mg [1800 mg orally twice daily] on the first day, followed by 800 mg
orally twice daily, up to a maximum of 14 days) as a part of their treatment. The primary endpoints were to evaluate the safety of
favipiravir by assessing the number of adverse events (AEs) and treatment-related AEs. The secondary endpoints were to evaluate the
efficacy of favipiravir by assessing time to clinical cure, rate of clinical cure, time to pyrexia resolution, rate of oxygen requirement,
and all-cause mortality.
Results: A total of 1083 patients were enrolled in this study from December 2020 to June 2021. Adverse events were reported in 129
patients (11.9%), 116 (10.7%) of whom had mild AEs. Dose modification or withdrawal of favipiravir treatment was reported in four
patients (0.37%). The median time to clinical cure and pyrexia resolution was 7 and 4 days, respectively. A total of 1036 patients
(95.8%) exhibited clinical cure by day 14. Oxygen support was required by 15 patients (1.4%). One death was reported, which was
unrelated to favipiravir.
Conclusion: In the real-world setting, favipiravir was well-tolerated, and no new safety signals were detected.
Keywords:..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit